Q-omics provides the consensus-scored ARID2 profile across patient tissues and cancer cell-line models. ARID2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ARID2 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, ARID2 protein abundance shows 25,803 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LIHC, and LSCC as cancer lineages where ARID2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARID2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARID2 survival associations across molecular data types. ARID2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (11) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARID2 RNA expression–survival associations across cancer types. High ARID2 expression shows unfavorable associations in LIHC, but favorable associations in KIRC, HNSC, GBM, THYM and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for ARID2 RNA expression.
This table summarizes ARID2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ARID2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARID2 shows lower tumor expression in THCA and higher tumor expression in LIHC, HNSC, BRCA, CHOL and LUSC. The LIHC box plot shows higher ARID2 RNA expression in tumor versus normal tissue (log2 FC = +0.933, t-test p < 0.001).
This table shows molecular features associated with ARID2 in patient tissues and cancer cell lines. In patient samples, ARID2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ARID2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
